This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): efavirenz, EFV, Stocrin
Description: Sustiva (Efavirenz) is a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside, reverse tran-scriptase inhibitor (NNRTI). Sustiva binds directly to reverse transcriptase (RT) and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
Reported sales of Sustiva from Bristol Myers includes what is sold as part of Atripla (Sustiva makes up approximately 35% of Atripla).
Deal Structure: In 1994 Bristol Myers Squibb licensed the rights to market Sustiva in the United States, Canada, the United Kingdom, France, Germany, Ireland, Italy and Spain from Merck for a royalty based on a percentage of net sales.
Partners: Merck & Co., Inc.
Pink Sheet Gilead Moving Forward On Combo HIV Therapy
Additional information available to subscribers only: